☆ 4.6 Review

Ripretinib: A Review in Gastrointestinal Stromal Tumours as Fourth-or Later-Line of Therapy

DRUGS (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. G. Casali et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Review Oncology

New treatment strategies for advanced-stage gastrointestinal stromal tumours

Lillian R. Klug et al.

Summary: When Gastrointestinal Stromal Tumour (GIST) was identified as a distinct pathological entity, effective medical therapies were lacking, leading to poor prognosis. However, the discovery of KIT mutations and the development of TKIs revolutionized GIST treatment. Although there are approved drugs for treating advanced-stage GIST, challenges still remain and new therapeutic approaches are needed.

NATURE REVIEWS CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

Effects of CYP3A Inhibition, CYP3A Induction, and Gastric Acid Reduction on the Pharmacokinetics of Ripretinib, a Switch Control KIT Tyrosine Kinase Inhibitor

Xiaoyan Li et al.

Summary: This study evaluated the drug-drug interaction potentials of Ripretinib with itraconazole, rifampin, and pantoprazole. The results showed that concomitant use of itraconazole increased Ripretinib exposure, while concomitant use of rifampin decreased Ripretinib exposure, and pantoprazole coadministration had no effect on Ripretinib pharmacokinetics.

CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2022)

添加到收藏夹

Article Oncology

Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial

Sebastian Bauer et al.

Summary: This study compared the efficacy and safety of ripretinib and sunitinib in patients with advanced GIST previously treated with imatinib. The results showed that ripretinib was not superior to sunitinib in terms of progression-free survival (PFS), but it had fewer treatment-emergent adverse events and better tolerability.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Effect of hepatic impairment on the pharmacokinetics of ripretinib.

Xiaoyan Li et al.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

An updated review of the treatment landscape for advanced gastrointestinal stromal tumors

Shreyaskumar R. Patel et al.

Summary: In the past 20 years, significant progress has been made in the treatment of patients with GISTs using tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib, and regorafenib. The recent approvals of ripretinib and avapritinib have further expanded treatment options for patients.

CANCER (2021)

添加到收藏夹

Meeting Abstract Oncology

Ripretinib as ≥4th-line treatment in patients with advanced gastrointestinal stromal tumor: Long-term update from the phase III INVICTUS study

M. von Mehren et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Meeting Abstract Oncology

Dermatopathological review of cutaneous squamous cell carcinoma events in patients with gastrointestinal stromal tumors treated with ripretinib

A. Patel et al.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

Sebastian Bauer et al.

Summary: This study reports the genomic heterogeneity of tumors from patients with advanced GIST and evaluates the efficacy of ripretinib across different KIT/PDGFRA mutation subgroups. Ripretinib demonstrated progression-free survival benefit in all assessed subgroups, including those with wild-type KIT/PDGFRA by tumor tissue.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study

John R. Zalcberg et al.

Summary: This study reports the efficacy and safety of ripretinib intrapatient dose escalation (IPDE) to 150 mg b.i.d. after progressive disease (PD) among patients randomized to ripretinib 150 mg QD in the INVICTUS study. The findings suggest that ripretinib IPDE may provide additional clinical benefit with acceptable safety profile in this patient population.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial

Jean-Yves Blay et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib

Filip Janku et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Bryan D. Smith et al.

CANCER CELL (2019)

添加到收藏夹

Article Pathology

The incidence, mutational status, risk classification and referral pattern of gastro-intestinal stromal tumours in the Netherlands: a nationwide pathology registry (PALGA) study

Arie J. Verschoor et al.

VIRCHOWS ARCHIV (2018)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri et al.

LANCET (2013)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Cardiac & Cardiovascular Systems

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

Ming Hui Chen et al.

CIRCULATION (2008)

添加到收藏夹

Article Oncology

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors

Michael C. Heinrich et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

添加到收藏夹

Article Oncology

PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib

CL Corless et al.

JOURNAL OF CLINICAL ONCOLOGY (2005)

添加到收藏夹

Review Oncology

Cutaneous side-effects of kinase inhibitors and blocking antibodies

C Robert et al.

LANCET ONCOLOGY (2005)

添加到收藏夹

Article Oncology

Imatinib: a selective tyrosine kinase inhibitor

PW Manley et al.

EUROPEAN JOURNAL OF CANCER (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.